Deep vein thrombosis screening

Revision as of 14:55, 24 August 2011 by WikiBot (talk | contribs)
Jump to navigation Jump to search

Deep Vein Thrombosis Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Deep vein thrombosis from other Diseases

Epidemiology and Demographics

Risk Factors

Triggers

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Approach

Assessment of Clinical Probability and Risk Scores

Assessment of Probability of Subsequent VTE and Risk Scores

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Venography

CT

MRI

Other Imaging Findings

Treatment

Treatment Approach

Medical Therapy

IVC Filter

Invasive Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Special Scenario

Upper extremity DVT

Recurrence

Pregnancy

Trials

Landmark Trials

Case Studies

Case #1

Deep vein thrombosis screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Deep vein thrombosis screening

CDC on Deep vein thrombosis screening

Deep vein thrombosis screening in the news

Blogs on Deep vein thrombosis screening

Directions to Hospitals Treating Deep vein thrombosis

Risk calculators and risk factors for Deep vein thrombosis screening

Value of screening

In-spite of identifying patients at increased risk of VTE, there is no clear clinical value for screening, the following reason explains

  • The strongest risk factor for VTE recurrence is the prior VTE event itself.
  • After discontinuation of warfarin in VTE patients, especially where the cause was unknown, there are still at high risk of recurrence. irrespective of the presence of inherited thrombophilia.
  • Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members outside of high risk situations.